A Pilot Proof of Concept Single-Center Study of the Use of Oritavancin in Systemic Staphylococcus aureus Infections in Patients with Opioid Use Disorder

Brief description of study

The study participants will be in the study for approximately 2 months including the screening, intervention phase and the 6 weeks of follow-up time

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Staphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis
  • Age: - 99 Years
  • Gender: All
Updated on 30 Jan 2020. Study ID: 831334

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center